Bencich John 4
4 · AEON Biopharma, Inc. · Filed Apr 3, 2026
Research Summary
AI-generated summary of this filing
AEON Biopharma CFO John Bencich Receives RSU Award
What Happened John Bencich, Chief Financial Officer of AEON Biopharma, was granted 754,717 restricted stock units (RSUs). The reported acquisition price is $0.00, which reflects that this is a compensation award (not an open-market purchase). The grant was reported on the Form 4 filed April 3, 2026, covering the award dated April 1–2, 2026.
Key Details
- Transaction type: Award/Grant (code A) — restricted stock units (RSUs).
- Grant amount: 754,717 RSUs; reported price $0.00 (no cash paid).
- Grant/Report dates: Grant Date per footnote April 1, 2026; Form 4 filed April 3, 2026; transaction reported for period April 2, 2026.
- Vesting: RSUs vest in substantially equal installments on each of the first, second, third and fourth anniversaries of the April 1, 2026 Grant Date, subject to continued service.
- Shares owned after transaction: Not disclosed in the excerpt of the filing provided.
- Filing timeliness: Form 4 was filed promptly (filed Apr 3 for an early-April grant); no late filing flag noted.
Context RSU grants are a common form of executive compensation and do not represent an immediate market purchase or sale. The award creates potential future share ownership as units vest; their ultimate value will depend on AEON’s stock price at vesting and any applicable tax or withholding arrangements. This filing is informational about compensation, not a directional market trade.
Insider Transaction Report
- Award
Class A Common Stock
[F1]2026-04-02+754,717→ 754,717 total
Footnotes (1)
- [F1]Represents an award of restricted stock units granted on April 1, 2026 (the "Grant Date"), which vest in substantially equal installments on each of the first, second, third and fourth anniversary of the Grant Date, subject to continued service through the applicable vesting date.